AFT Pharmaceuticals Limited (AFP) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome, everybody, to AFT Pharmaceuticals' full year 2024 results briefing. Joining us today are Dr. Hartley Atkinson, Chief Executive Officer of AFT Pharmaceuticals, and Malcolm Tubby, Chief Financial Officer of AFT Pharmaceuticals. Before we begin, please note that any forward-looking statements mentioned on this call are based on management's current expectations and observations and are subject to risk and uncertainties that can cause actual results to differ from the forward-looking statement. AFD Pharmaceuticals does not undertake any obligation to update publicly any forward-looking statements to reflect the events or change circumstances after the call. With that, I will turn over the call to the speakers. Dr. Atkinson, please go ahead. Welcome, everyone. Thank you for joining us today. Just going to move through the investor presentation. This is for the last financial year, which is the period that goes to the 31st of March, 2024. And we've already essentially been through the disclaimer, so I'll take it that you've read that. Thank you. And then, as we've mentioned, presenting today is myself, Hartley Atkinson, and Malcolm Tubby our chief financial officer. And moving on to the summary page, as you can see, we are pleased to report record revenue, record earnings, and also lowering debt. And this occurred even with considerable investment as well to expand the business. So basically, if you look at actually on the left, that bottom graph, You know, maybe that gives you some indication, if anything, we're starting to see escalating growth over the last sort of two or three years. And overall, too, we've roughly quadrupled sales over 10 years and roughly doubled sales over four years. Historically, we've grown the business significantly and going forward, a...